777 reports of this reaction
1.6% of all MINOCYCLINE HYDROCHLORIDE reports
#7 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #7 most commonly reported adverse reaction for MINOCYCLINE HYDROCHLORIDE, manufactured by Melinta Therapeutics, LLC. There are 777 FDA adverse event reports linking MINOCYCLINE HYDROCHLORIDE to DRUG HYPERSENSITIVITY. This represents approximately 1.6% of all 49,345 adverse event reports for this drug.
Patients taking MINOCYCLINE HYDROCHLORIDE who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is a less commonly reported adverse event for MINOCYCLINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to drug hypersensitivity, the following adverse reactions have been reported for MINOCYCLINE HYDROCHLORIDE:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 777 FDA reports for MINOCYCLINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 1.6% of all adverse event reports for MINOCYCLINE HYDROCHLORIDE, making it a notable side effect.
If you experience drug hypersensitivity while taking MINOCYCLINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.